MDX RA: 4197X-RA, Monoclonal Antibody Ricin A

Author：  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.3, Iss.2, 2002-02, pp. : 111-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

According to The British Society for Rheumatology guidelines, 5.6% of outpatients with rheumatoid arthritis (RA) in the West Midlands, UK, are eligible for anti-tumour necrosis factor (TNF) monoclonal antibody therapy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 422, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Are full or modified HAQ QOL questionnaires best in RA?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 318, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

TNF- inhibitors: `new era' of biological therapies for RA?

By  

Inpharma, Vol. 1, Iss. 1267, 2000-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Etanercept in RA: will it crack the early disease market?

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Is early intervention with biological agents worthwhile in RA?

By  

Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite